Chargement en cours...
Unveiling changes in the landscape of patient populations in cancer early drug development
The introduction of new Molecularly Targeted Agents (MTA) has changed the landscape in Early Drug Development (EDD) over the last two decades, leading to an improvement in clinical trial design. Previous Phase 1 (Ph1) studies with cytotoxics focused on safety objectives, only recruiting heavily pre-...
Enregistré dans:
| Publié dans: | Oncotarget |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Impact Journals LLC
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5355170/ https://ncbi.nlm.nih.gov/pubmed/27835915 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13258 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|